Thus, our study also provided a potential treatment strategy, i.e., a combination of PYK2 inhibitor PF562271 with the BRAF inhibitor, vemurafenib, that may be an effective therapy to prolong the survival of patients with vemurafenib resistant melanomas. This evidence concerns the gene BRAF and melanoma.